

At page 49, line 6, insert --primer analysis-- after "4.06".

At page 50, line 21, replace "Peptide Synthesizer Model 431A" with --431A peptide synthesizer--.

IN THE CLAIMS


Please cancel claims 3-11, 19, and 20 without prejudice.

REMARKS

Applicants have amended the claims to remove inadvertent typographical errors. Applicants respectfully request entry of the present amendments to the claims. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned associate counsel of record at (650) 845-4842. No new matter has been added by these amendments.

If the USPTO determines that a fee is due, the Commissioner is hereby authorized to charge Incyte Pharmaceuticals, Inc. Deposit Account No. 09-0108. This form is enclosed in duplicate.

Respectfully submitted,
INCYTE PHARMACEUTICALS, INC.


Sheela Mohan-Peterson

Reg. No. 41,201

Direct Dial Telephone: 650-845-4842

Date: March 9, 1999

3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 845-4842
Fax: (650) 849-8886